Cowen and Company’s Orphazyme A/S ORPH Stock Holding History

Cowen and Company’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,500	Closed	-$5K	–	835
2021 Q2	$5K	Buy	+2,500	New	+$20.1K	﹤0.01%	563

Other funds holding ORPH

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

BAM

Blueshift Asset Management Red Bank, New Jersey $330M AUM 7.9% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cowen and Company's ORPH Position: Q3 2021 in Review

Cowen and Company sold out of Orphazyme A/S (ORPH) in Q3 2021, closing a stake of 2,500 shares — an estimated $18K sold.

Cowen and Company first reported a position in ORPH in Q2 2021 and held it in 1 quarter. The position peaked at $18K in Q2 2021. 22 funds tracked by Wall St. Rank hold ORPH as of Q3 2021.

Cowen and Company reported no remaining Orphazyme A/S position as of Q3 2021 after selling out during the quarter.
Cowen and Company sold 2,500 Orphazyme A/S shares in Q3 2021, an estimated $18K.
Cowen and Company first reported a position in Orphazyme A/S in Q2 2021 and held it in 1 quarter.
Cowen and Company's Orphazyme A/S position peaked at $18K in Q2 2021.
22 funds tracked by Wall St. Rank held Orphazyme A/S as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.